Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
We are very pleased with the results, which potentially demonstrate that nerve blocks with our NaV1.7 inhibitors may be ...
FierceBiotech13d
Novo Holdings leads SiteOne's $100M series C for non-opioid pain treatments
SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target ...
Business Insider11d
Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine
“While both NaV1.7 and NaV1.8 are voltage-gated sodium channels mainly expressed in sensory neurons, there are important differences in their roles in pain transmission. Research indicates that an ...
pharmaphorum13d
Novo Holdings leads $100m round for novel painkiller biotech
The Series C – which was led by Novo Nordisk's parent company Novo Holdings – follows a $15 million second round for the ...
The Pharma Letter12d
Vertex Phase II suzetrigine study disappoints
US biopharma Vertex Pharmaceuticals today announced results from its Phase II study of suzetrigine, an investigational, oral, ...
BioSpace12d
Vertex Dips on Mixed Phase II Data for Non-Opioid Pain Therapy
Vertex Pharmaceuticals’ investigational non-opioid analgesic suzetrigine failed to outperform placebo. Investors voiced their ...
Morningstar11d
Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine
“While both NaV1.7 and NaV1.8 are voltage-gated sodium channels mainly expressed in sensory neurons, there are important differences in their roles in pain transmission. Research indicates that ...